Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER¿S DISEASE

Intervention/treatment:
GANTENERUMAB (RO4909832)/ [18F]GTP1/ FLUTEMETAMOL (18F)
Medical condition:
ALZHEIMER'S DISEASE
Protocol code:
WN29922
Control number:
216415
Status:
Closed
Approved:
June 15, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03444870
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
50 Years to 90 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Medical Communications
Organization
Hoffmann-La Roche
Phone:
800 821-8590
Sponsor
HOFFMANN-LA ROCHE LIMITED

Locations

Alpha Recherche Clinique
Québec, G3K 2P8

British Columbia

Medical Arts Health Research Group
Penticton, British Columbia, V1Y 1Z9
The Medical Arts Health Research Group - West Vancouver
Vancouver, British Columbia, V7T 2Z3

Ontario

Baycrest Health Sciences
Toronto, Ontario, M6A 2E1
Centre for Memory and Aging
Toronto, Ontario, M4G 3E8
Devonshire Clinical Research
Woodstock, Ontario, N4S 5P5
Parkwood Hospital; Geriatric Medicine
London, Ontario, N6C 5J1
St. Michael'S Hospital
Toronto, Ontario, M5B 1W8
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5

Quebec

Center for Diagnosis and Research on Alzheimer's disease
Greenfield Park, Quebec, J4V 2J2
Q & T Research Sherbrooke
Sherbrooke, Quebec, J1J 2G2

Results

See the results from the trial NCT03444870. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?